13D Filing: James E. Flynn and Alpine Immune Sciences Inc. (ALPN)

Page 8 of 13

Page 8 of 13 – SEC Filing

SCHEDULE 13D

CUSIP No.  02083G100 Page 8 of 13 Pages
1

NAME OF REPORTING PERSONS

Deerfield Management Company, L.P.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☒

3

SEC USE ONLY

4

SOURCE OF FUNDS

AF

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

936,175 (2)

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

936,175 (2)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

936,175 (2)

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

6.74%

14

TYPE OF REPORTING PERSON

PN

(2) Comprised of 281,184 shares held by Deerfield Special Situations
Fund, L.P., 100,515 shares held by Deerfield Private Design Fund, L.P., 161,788 shares held by Deerfield Private Design International,
L.P., 181,560 shares held by Deerfield Private Design Fund II, L.P., 208,053 shares held by Deerfield Private Design International
II, L.P. and 3,075 shares of Common Stock underlying an option held by Howard P. Furst, a partner in Deerfield Management Company,
L.P. and a director of the Issuer.

Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)

Page 8 of 13